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Membrane type-I metalloproteinase (MT1-MMP) is a transmembrane metalloproteinase that is critical for tumor cell
invasion. MT1-MMP can degrade extracellular matrix (ECM) proteins directly and/or indirectly by activating soluble
MMPs such as pro-MMP-2. Although MT1-MMP is upregulated in malignant melanoma, the biological consequences
of elevated MT1-MMP expression for tumor progression are not enirely understood. In the current study, we have
utilized the Bowes melanoma line for evaluating MT1-MMP in invasion and growth. Our studies extend the earlier
observations to demonstrate that MT1-MMP expression in Bowes melanoma cells promotes selective invasion into
matrigel but not matrices consisting of type-I collagen. Furthermore, MT1-MMP expressing melanoma cells exhibit
increased migration in response to laminin 1 but not to type-I or type-IV collagen. MT1-MMP expression results in
enhanced 3 dimensional growth in agarose gels and in long-term cultures within matrigel. The hydroxymate
inhibitor BB94 inhibits MT1-MMP enhanced invasion and growth in 3 dimensional culture systems, but had no
effect on increased motility. We demonstrated that MT1-MMP expression signiﬁcantly facilitated tumorigenicity and
growth by intradermal injection. The results suggest a more general role for elevated MT1-MMP in promoting both
the selective invasion and increased growth of malignant melanoma in vivo.
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Degradation of extracellular matrix (ECM) proteins is tightly
linked to tumor invasion and metastasis (Rudolph and
Matrisian, 1998). Matrix metalloproteinases (MMP) are a
family of zinc-dependent proteases critical for tumor
progression, invasion, and metastasis (Sato et al, 1997).
MMP are subgrouped into soluble MMP and membrane-
anchored MMP (membrane-type MMP, MT-MMP) (Nagase
and Woessner, 1999). Soluble MMP are thought to be
responsible for ECM degradation over relatively broad areas
within tissues, whereas MT-MMP participate in pericellular
degradation of ECM, as they are tethered to the plasma
membrane (Sato et al, 1997; Nagase and Woessner, 1999).
Although the exact functions of these enzymes in tumor
invasion and metastasis are not entirely understood,
degradation of ECM proteins in the tumor microenvironment
functions to provide space for growing tumors both within
primary and metastatic tumors (Rudolph and Matrisian,
1998). More recently, MMP activation has been linked to
specific biologic mechanisms of tumor progression, includ-
ing cell proliferation, resistance to apoptosis, and increased
angiogenesis (McCawley and Matrisian, 2001).
Melanomas are malignant tumors that usually arise in the
epidermis of the skin (Houghton and Polsky, 2002). The
invasion of melanomas from the epidermis to the dermis
requires degradation of basement membrane components
that are substrates for several MMP (Stetler-Stevenson
et al, 1993; MacDougall and Matrisian, 1995; Nagase and
Woessner, 1999). Increased expression of MMP has been
linked to progression and invasion in melanomas (Hofmann
et al, 2000). Elevated levels of MMP-2 and MMP-9 have
been correlated with melanoma invasion both in vitro and
in vivo (Hofmann et al, 1999; Itoh et al, 1999; MacDougall
et al, 1999). Endogenous inhibitors of MMP, known as tissue
inhibitors of matrix metalloproteinases (TIMP) inhibit mela-
noma cell growth and invasion. For example, overexpres-
sion of TIMP-1 and TIMP-3 in melanoma cells inhibits tumor
formation in animal models (Khokka, 1994; Ahonen et al,
1998). Valente et al (1998) overexpressed TIMP-2 and
inhibited both invasion and angiogenesis of melanomas
in vivo. Histopathologic analysis of human tumor samples
shows that MT1-MMP is expressed in melanoma cells and
localizes to tumor cells at the invasive front of primary
tumors (Hofmann et al, 2000). Furthermore, MMP-2 is
colocalized with MT1-MMP, suggesting that MT1-MMP and
MMP-2 act in concert to mediate melanoma invasion in vivo
(Hofmann et al, 2000). MT1-MMP expression in A2058
melanoma cells has recently been linked to activation of
pro-MMP2 and increased tumor formation in vivo (Sounni
et al, 2002a). These results collectively emphasize the
importance of increased MMP expression and MT1-MMP-
Abbreviations: ECM, extracellular matrix; MMP, matrix
metalloproteinase.
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mediated activation of MMP in melanoma invasion and
progression.
Human tumor xenografts are supposed to be appropriate
models for addressing specific questions related to the
clinical behavior and treatment sensitivity of human tumors.
Melanocytes are normally found in the dermal–epidermal
junction of the skin, thus tumor growth in orthotopic sites
was achieved by intradermal injection of melanoma cells.
Indeed, previous studies demonstrated that different mel-
anoma cells grown in subdermal sites retained several
biologic characteristics of the donor patients’ tumors,
including angiogenic potential, growth, histopathologic
parameters, and the organ-specific metastatic pattern
(Cornil et al, 1989; Rofstad, 1994). These results suggest
that the intradermal injection of melanoma cells show a
great promise for future studies of tumor angiogenesis,
pathology, and metastatic phenotype.
In this study we have characterized the in vitro invasion
and growth of Bowes melanoma cells stably transfected
with MT1-MMP. Expression of MT1-MMP stimulates mela-
noma invasion into three-dimensional matrices composed
of basement membrane components (matrigel) but not
native type I collagen, suggesting that the collagenolytic
activity of MT1-MMP is insufficient to promote invasion
through native type I collagen. Additionally, MT1-MMP
expression results in increased migration to laminin-1 but
not to types I and IV collagens. MT1-MMP-mediated invasion
is sensitive to the MMP inhibitor BB94, whereas increased
migration to laminin-1 is resistant. Furthermore, MT1-MMP
expressing melanoma cells exhibit increased growth in both
two-dimensional and three-dimensional cultures, which is
also inhibited by BB94. Increased colony growth is also
observed for MT1-MMP expressing melanoma cells em-
bedded and cultured long-term within matrigel. We demon-
strated that MT1-MMP expression significantly facilitated
tumor take and growth by orthotopic injection (intradermal
injection). The results suggest a more general role for
elevated MT1-MMP in promoting both the selective inva-
sion and increased growth of malignant melanoma in vivo.
Results
Characterization of MT1-MMP-mediated activation of
pro-MMP-2 expressed in Bowes melanoma cells Bowes
melanoma cells have been reported to express very low
amounts of MT1-MMP and produce MMP-2 as a zymogen
form as described previously (Lehti et al, 2000). We
therefore chose these cells to transfect with a plasmid
harboring the coding sequence for human MT1-MMP. We
generated stable cell lines as well as cells transfected with a
GFP-vector alone to serve as a control. MT1-MMP was
expressed in the stable transfectants as three major
proteins migrating at 65 kDa, 60 kDa, and 44 kDa on
SDS–PAGE (Fig 1A). Two higher molecular weight immuno-
reactive fragments of 65 kDa and 60 kDa remained
following treatment of BB94. These two higher molecular
weight species represent the pro- and active-forms,
respectively, of MT1-MMP and they are detected in cells
either treated or not with BB94. In contrast, cultures treated
overnight with BB94 lacked the lower (44 kDa) band present
in nontreated cultures (Fig 1A). These results agree with
previous studies demonstrating that autocatalytic degrada-
tion of MT1-MMP creates a 44 kDa membrane tethered
fragment that lacks catalytic activity (Lehti et al, 2000). In
contrast, the expression of the 60 kDa active form of MT1-
MMP is facilitated by intracellular furin-dependent mechan-
isms and is resistant to hydroxymate inhibitors (Lehti et al,
2000).
We analyzed the activation status of endogenous pro-
MMP-2 using gelatin zymography to evaluate the catalytic
activity of MT1-MMP (Fig 1B). As expected, MT1-MMP
expression caused a corresponding activation of MMP-2 to
yield both intermediate (i) and active (a) forms of the
gelatinase. Production of these forms was inhibited in the
presence of BB94, indicating the requirement for MMP
activity in the processing of pro-MMP-2. Thus, these results
indicate that MT1-MMP transfected into melanoma cells is
expressed and functionally active on the cell surface, which
is consistent with previous studies demonstrating that MT1-
MMP activates pro-MMP-2 in various cell types (Lehti et al,
2000; Yana and Weiss, 2000; Sounni et al, 2002a,b). Recent
studies have also suggested that serine proteases such as
plasmin can activate MMP-2 in the presence of MT1-MMP
(Monea et al, 2002; Sounni et al, 2002a); however,
incubation of MT1-MMP expressing melanomas with either
aprotonin or e-amino-n-caproic acid failed to inhibit the
activation of MMP-2 in these cells (Fig 1B). These results led
us to conclude that pro-MMP-2 activation is not dependent
on plasmin activation by these cells, but rather is dependent
on the catalytic activity of MT1-MMP on the cell surface.
MT1-MMP mediated melanoma invasion into matrigel
but not type I collagen In order to characterize further the
importance of MT1-MMP in melanoma invasion, melanoma
cells were cultured on top of matrigel and invaded cells
were counted as a function of the depth of their invasion.
The number of invading cells was determined by quantifying
the number of cells at successive 20 mm (1 cell diameter)
depths in six randomly selected fields (Faassen et al, 1992).
As demonstrated in Fig 2(A), almost all cells (95%) in mock-
transfected melanoma cells remained on the top or within
the first 20 mm deep layer of the gels. Only 5% of cells
invaded to a level of 40 mm depth in these gels. In contrast,
almost half (48%) of the MT1-MMP expressing cells
invaded into the gel at a depth of more than 40 mm and
10% of cells invaded to depths as far as 80 to 100 mm
beneath the gel surface (Fig 2A). Invasion of MT1-MMP
expressing melanoma cells was significantly inhibited in the
presence of BB94 (Fig 2A). These results are consistent with
the previous studies in which expression of MT1-MMP
promotes invasion of multiple tumor cell types by a
mechanism dependent on the catalytic function of the
protease (Sato et al, 1994; Nakahara et al, 1997; Lehti et al,
2000; Sounni et al, 2002a,b).
Type I collagen is enriched in dermis and melanoma cells
must penetrate this structure as they progress and exit the
epidermis (Benbow et al, 1999). Previous studies demon-
strate MT1-MMP expression and collagenolytic activity of
this protease is essential for promoting the invasion of
various cell types into type I collagen gels (Hotary et al,
2000; Aznavoorian et al, 2001; Ellerbroek et al, 2001; Zhuge
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and Xu, 2001). Under our experimental conditions, however,
we did not observe invasion of MT1-MMP transfectants into
type I collagen gels (Fig 2B), suggesting that there are cell
type specific differences in the importance of MT1-MMP in
mediating invasion into type I collagen.
MT1-MMP enhanced migration to laminin-1 but not to
types I and IV collagens Laminins are a major component
of basement membranes and play an active part in tumor
metastasis, cell attachment and migration, and angiogen-
esis (Patarroyo et al, 2002; Yamamura et al, 1993; Snow
and Smith et al, 2002). Invasion of MT1-MMP expressing
melanoma cells into matrigel was significantly inhibited by
specific neutralizing antibodies against a6 integrin but not
with anti-a2 or a3 integrin antibodies (not shown), suggest-
ing that laminin-1/a6b1 interactions play a key part in
promoting melanoma invasion into matrigel. We therefore
subjected melanoma cells to migration assays in which
laminin-1 was used as an attractant. Although mock-
transfected melanoma cells showed relatively low migratory
responses to laminin-1, MT1-MMP expressing melanoma
cells exhibit a significant increase (4–5-fold) in migration
(Fig 3A). Transfection of MT1-MMP into Bowes melanoma
cells did not alter expressions of a2b1, a3b1, and a6b1
integrins (not shown). As expected, migration of mock-
transfected and MT1-MMP-transfected melanoma cells
was inhibited by the addition of anti-a6 or anti-b1 integrin
antibody but not by the addition of anti-a2 integrin antibody
(Fig 3B). These results suggest that increased invasion into
matrigel is also dependent on the interaction of a6b1 with
laminin-1, which is a major component of matrigel. It is of
interest that BB94 failed to inhibit migration to laminin-1 by
MT1-MMP expressing melanoma cells (Fig 3A), although it
did inhibit the invasion of these cells into matrigel. These
results indicate that invasion into matrigel depends on both
proteolytic and adhesion-related mechanisms. The results
also suggest that MT1-MMP may stimulate motility by
directly altering signal transduction pathways within mela-
noma cells, as the catalytic activity of the protease is not
required for increased motility. The results also suggest
Figure 1
Expression of MT1-MMP in melanoma cells and activation of endogenous pro-MMP-2. Melanoma cells were transfected with vector (mock) or
vector harboring carboxyl terminal flag-tagged MT1-MMP (MT1-MMP). Transfectants were sorted as described in Materials and Methods and
cultured to generate stable transfectants. Cells (5  105 cells) were lyzed and proteins were separated on SDS–PAGE. (A) The membranes were
blotted with anti-flag M2 antibody following by horseradish peroxidase-conjugated goat anti-mouse IgG. Immunoreactive bands were visualized
using enhanced chemiluminescence as described. Molecular weight markers are shown as (kDa). (B) Overnight conditioned media collected from
mock and MT1-MMP expressing melanoma cells were analyzed by gelatin zymography as described in Materials and Methods. In certain cultures,
proteinase inhibitors were added to the media for the entire duration of the overnight culture. These inhibitors included 5 mM BB94 (MMP inhibitor),
100 mg per mL aprotinin (Apro.) (serine protease inhibitor), and 200 mg per mL e-amino-n-caproic acid (ACA) (serine protease inhibitor). The standard
conditioned media (concanavalin A-stimulated HT1080 cells) was also included in the zymogram to localize the pro-form (p), intermediate-form (i),
and active-form (a) of MMP-2.
Figure 2
Invasion into matrigel and type I collagen by
melanoma cells expressing MT1-MMP. Melanoma
cells were harvested and cultured on matrigel (A) or
type I collagen gel (B) as described in Materials and
Methods. The number of invading cells was deter-
mined using an inverted microscope with a calibrated
fine focus knob. The number of cells at successive 20
mM (1 cell diameter) intervals in six randomly selected
fields was quantified. Quantitation was made at
increasing depth within the gels until no additional
cells were detected. BB94 was included in certain
cultures at a final concentration of 5 mM. At least 100
cells were counted from each group and data are
represented as the percentage of cells penetrating
the gels. Experiments were repeated three times and
results are represented as means.
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some level of specificity in this response, as enhanced
migration to type I (Fig 3C) or type IV collagens (Fig 3D) is
not enhanced by the expression of MT1-MMP.
MT1-MMP enhances growth of melanomas We next
tested the ability of MT1-MMP expressing cells to grow in
culture, as increased growth is associated with progression
and invasion (Freedman and Shin, 1974; Cifone, 1982).
MT1-MMP expressing Bowes melanoma cells plated in
two-dimensional culture conditions exhibited significant
increases in growth relative to cells containing the vector
alone (Fig 4A). The cells exhibited equal plating efficiencies
as judged in part by the equal number of cells observed in
all cultures within the first 3 d of plating. Growth of MT1-
MMP expressing cells was consistently elevated by 20% or
greater relative to vector controls when analyzed on days 5,
7, and 10 following plating (Fig 4A). The addition of BB94 to
these cultures inhibited the accelerated growth of the tumor
cells to levels observed in the vector control cultures
(Fig 4A). BB94 treated cultures did not show decreased via-
bility relative to nontreated cultures (not shown), suggesting
that MMP catalytic activity in the cultures is required for
increased growth of the cells.
We also performed growth assays in semisolid media
(i.e., agarose). Melanoma cells cultured in this medium form
tightly packed colonies after 10 d in culture (not shown).
MT1-MMP expressing cells exhibit highly significant
(po0.001) increases in colony numbers when compared
with vector-transfected controls (Fig 4B). Importantly this
increased propensity to form colonies in semisolid medium
was also inhibited by the addition of BB94 (Fig 4B). These
results indicate that MT1-MMP expression leads to in-
Figure3
Migration to ECM proteins by melanoma cells
expressing MT1-MMP. Melanoma cells were harvested
and subjected to migration assays for laminin-1, type I
collagen (C), or type IV collagen (D). Migration (A, B)
assays were performed for 4 h using transwells as
described. The number of cells migrating to the lower
surface of the membranes was estimated by counting
the number of cells in three random fields on each
membrane. BB94 was included in the assays at a final
concentration of 5 mM. Antibodies against integrin
subunits containing anti-a2, anti-a6, and anti-b1 were
included at a final concentration of 5 mg per mL.
Experiments were repeated at least three times and
results are expressed as mean  SD from one repre-
sentative experiment (po0.001).
Figure 4
Growth of melanoma cells expressing MT1-MMP. (A) Melanoma cells were plated in 12-well plates at density of 2  104/2 mL per well in EMEM
culture media. Cells were cultured for 10 d in growth media, and the media were changed in these cultures every other day. The numbers of cells in
each well were counted using a hemocytometer on the indicated days. BB94 was included in the assays at a final concentration of 5 mM.
Experiments were repeated at least three times and results are expressed as mean  SD from one representative experiment. (B) Growth of cells
suspended in agarose was also determined as described. The cultures consisted of 5000 viable cells (suspended in 0.3% agarose of EMEM
supplemented with 10% FBS, nonessential amino acids, and sodium pyruvate) that were overlaid on a 1% agarose layer in six well-plates. Ten days
after seeding, colonies over 100 mm in diameter were counted under a light microscope. BB94 was included in the assays at a final concentration of
5 mM. The data are presented as the mean and SD of triplicates plates. po0.001, po0.05, not significant.
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creased colony forming potential of these cells, which is a
correlate of tumorigenic potential. Furthermore, the in-
creased colony forming potential of MT1-MMP expressing
cells is also dependent on MMP catalytic activity within the
cultures, which is similar to what was observed in two-
dimensional cultures.
Many studies indicate that basement membranes may
serve as barriers for preventing tumor cell entry into
adjacent tissues (Yamamura et al, 1993; Durko et al,
1997). We therefore next evaluated the growth of the
MT1-MMP expressing melanomas, cultured in matrigel for
7 d, to determine if increased growth is also observed in a
more complex microenvironment that is rich in basement
membrane components. Under these experimental condi-
tions, the colony numbers between mock and MT1-MMP
expressing melanoma cells were similar (not shown),
however, the MT1-MMP expressing cells exhibited much
larger colonies than the vector control cells (Fig 5). These
results suggest that MT1-MMP expression in melanoma
cells may facilitate growth of melanoma cells at tissue
boundaries, accelerating entry of tumor cells into adjacent
tissues via a growth-related mechanism.
MT1-MMP enhanced melanoma growth in vivo Intrader-
mal (i.d.) injections in mice were performed with mock-
transfected or MT1-MMP expressing melanoma cells. Tumor
sizes were monitored up to 40 d as described in Materials
and Methods. Under these experimental conditions, MT1-
MMP expressing melanoma cells formed palpable tumors in
65% of total injected sites within 19 d following injection (Fig
6). By contrast, mock-transfected melanoma cells formed
tumors at a much slower rate. Only 30% of total injected
sites formed a detectable tumor within 19 d following
injection. The number of sites with tumors increased slowly
over the next 26 d, finally reaching a maximum (18 of 20) at
day 40 (Fig 6). The size of the tumors formed within 40 d by
the MT1-MMP expressing cells was also significantly larger
than those formed by the mock-transfected cells (Fig 7). The
average estimated volume of the MT1-MMP expressing
tumors was 160  60 (mean  SD), whereas the size of the
mock-transfected tumors was 96  76 (mean  SD). These
results suggest that elevated MT1-MMP expression may
enhance the growth of tumors in vivo within sites harboring
primary melanoma tumors.
Discussion
Dysregulated expression of MMP is a critical contributing
factor to the invasion and progression of malignant tumors
(Rudolph and Matrisian, 1998; Hornebeck et al, 2002). MMP
first received attention because of their ability to degrade
ECM components. The degradation of ECM by tumor (or
stroma) associated matrix metalloproteinases was thought
to facilitate growth and invasion by providing space for the
expanding neoplasm (Rudolph and Matrisian, 1998; Horne-
beck et al, 2002); however, more recently, proteases have
been linked to a number of processes not directly
associated with ECM degradation such as activation of
latent forms of growth factors and alteration of Fas-ligand-
mediated apoptosis (McCawley and Matrisian, 2001). Thus,
catalytic activities of MMP produced by tumor cells may
play a part in invasion and metastasis not only by degrading
ECM proteins but also by stimulating tumor growth, sur-
vival, and evasion from immune surveillance mechanisms.
Figure5
Colony morphology in matrigel by melanoma cells expressing
MT1-MMP. Colony morphology in matrigel was studied by embedding
melanoma cells (104 cells per mL) within matrigel (4 mg per mL). The
suspended cells were added to 24 well plates (1 mL per well) and the
matrigel was allowed to gel at 371C. Cultures were incubated in a
humidified 5% CO2 incubator at 371C for 7 d and media were changed
every other day. Resulting colonies were observed and photographed
using an inverted phase contrast microscope equipped with a digital
camera as described in Materials and Methods. BB94 was included in
these assays at a final concentration of 5 mM. Photomicrographs shown
are representative of colonies observed in each culture condition. Scale
bars¼ 100 mm.
Figure6
Tumor intake by melanoma cells expressing MT1-MMP. MT1-MMP
expressing (open circles) or mock-transfected (closed circles) melano-
ma cells were injected intradermally into both right and left flanks (105
cells per 10 mL per site) as described in the Materials and Methods
section. Animals were monitored every 3 to 4 d for the presence of
tumors. Mice were examined every 3 to 4 d for the presence of
palpable tumors for 40 d. Shown is the percentage of injected sites
exhibiting palpable tumors on any given day (i.e., tumorigenicity).
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MT1-MMP has been localized to the tumor–stroma
interface of primary melanomas (Hofmann et al, 2000). In
this study, we demonstrate that MT1-MMP expression
promotes melanoma invasion into matrigel, consistent with
previous studies using melanomas or other tumor types
(Lehti et al, 2000; Sounni et al, 2002a,b). Furthermore,
migration to laminin-1, but not to types I and IV collagens,
was also enhanced by MT1-MMP expression. Finally, MT1-
MMP promoted melanoma growth in two-dimensional
cultures; it also enhanced colony formation in agarose
cultures and caused increased growth of tumor cells
embedded within matrigel. Increased invasion and growth
required MMP catalytic activity within the cultures, whereas
enhanced migration facilitated by MT1-MMP expression
was resistant to inhibitors of MMP catalytic function. These
results suggest that MT1-MMP may facilitate tumor
progression by activating invasion, migration, and growth
in the vicinity of basement membranes, facilitating entry of
melanoma cells across tissue boundaries by multiple
mechanisms.
The processing of MT1-MMP zymogen activation has
been widely studied in various cell types including normal
and tumor cells (Lehti et al, 2000; Yana and Weiss, 2000;
Sounni et al, 2002a,b). We observed that MT1-MMP is
expressed as three proteins based on the molecular
masses on SDS–PAGE. As the 44 kDa fragment of MT1-
MMP is detected by anti-flag antibody, the protein is likely
an N-terminal truncated fragment of the enzyme. Based on
previous studies, we predict that this is an MT1-MMP
fragment that lacks the zinc binding site and therefore lacks
catalytic activity (Lehti et al, 2000). In support of this
conclusion, the 44 kDa species was not detected by
blotting with an anti-catalytic domain monoclonal antibody
for MT1-MMP (not shown). The generation of the 44 kDa
form of MT1-MMP requires MMP catalytic activity, as BB94
completely inhibits its generation. It therefore likely repre-
sents a fragment of MT1-MMP that is produced as a result
of the autocatalytic downregulation of MT1-MMP on the cell
surface (Lehti et al, 2000).
Based on the predicted molecular masses on SDS–
PAGE, the 65 kDa and 60 kDa form of MT1-MMP are the
pro- and active-forms, respectively. The 60 kDa active form
of MT1-MMP is still observed in the presence of BB94,
indicating that an MMP-independent mechanism is respon-
sible for its generation. Previous studies have shown that
intracellular furin-related enzymes are important in many
cell types for regulating MT1-MMP activation (Yana and
Weiss, 2000). Several studies showed that a synthetic furin
inhibitor (CMK) can inhibit the processing of the MT1-MMP
proform to the active form (Maquoi et al, 1998; Kurschat
et al, 1999); however, this inhibitor is highly toxic in our
hands when added to these melanoma cell cultures (not
shown) preventing us from being able to draw any conclu-
sions with respect to the importance of furin-dependent
MT1-MMP processing in this system.
There is substantial evidence demonstrating that MT1-
MMP mediated activation of MMP-2 is important in
melanoma invasion and growth (Hofmann et al, 1999,
2000; Sounni et al, 2002a). Although MT1-MMP is a major
activator for MMP-2 (Sato et al, 1994), some studies also
implicate serine proteases (e.g., plasmin) in MMP-2 activa-
tion (Monea et al, 2002; Sounni et al, 2002a). Plasmin has
recently been reported to activate pro-MMP-2 by an MT1-
MMP-dependent mechanism that is independent of the
catalytic activity of MT1-MMP (Monea et al, 2002). Recent
studies have also shown that plasmin can generate the fully
active form of MMP-2 in A2058 melanoma cells expressing
MT1-MMP (Sounni et al, 2002a); however, based on our
data, we conclude that MT1-MMP activation of pro-MMP-2
in Bowes melanoma cells is independent of plasmin, as it
is resistant to aprotinin or e-amino-n-caproic acid. This
activation could occur possibly by a multistep mechanism
involving MT1-MMP-mediated production of the intermediate
form of pro-MMP-2 and the subsequent autocatalytic
activation of the intermediate form of MMP-2 as previously
proposed (Atkinson et al, 1995).
There are a number of studies showing that expression of
MT1-MMP is important in promoting invasion into matrigel;
these studies also emphasize the importance of activated
soluble gelatinases (MMP-2) in invasion (Lehti et al, 2000;
Sounni et al, 2002a,b). It is therefore not surprising that our
Bowes MT1-MMP transfectants exhibit increased invasion
into matrigel; however, it is somewhat surprising that
increased expression of MT1-MMP in these cells caused
no detectable increase in invasion of these cells into type I
collagen gels. Previous studies showed that MT-MMP
would play key parts in cell invasion into type I collagen
(Aznavoorian et al, 2001; Ellerbroek et al, 2001; Iida et al,
2001; Zhuge and Xu, 2001). Recently, Hotary et al (2000)
reported that expression of MT1-MMP in Madin–Darby–
Figure 7
Tumor growth by melanoma cells expressing MT1-MMP. Melanoma
tumor growth was measured using calipers, and the volume of the
tumors was estimated by the calculation described in the Materials and
Methods section. Shown are the calculated volumes of tumors at 40 d
postinjection. Each dot represents tumor volume at a distinct injection
site (two sites per mouse), and the horizontal line depicts the mean
calculated value for the entire group. The experimental group injected
with MT1-MMP expressing tumors contained three less values than the
control (mock-transfected group) (17 vs 20) because three of the
tumors in the MT1-MMP group were exceedingly large and judged to
be outliers based on the use of box-plot analysis (Williamson et al,
1989; Tukey, 1990). Statistical significance between the means of the
two groups of tumors was determined by the Student’s t-test.
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Canine Kidney cells, which lack expression of gelatinases
(such as MMP-2), directly promotes cell invasion into type I
collagen-rich matrices. These results were interpreted to
suggest that MT1-MMP by itself acts as a cell surface
associated collagenase, enhancing invasion by facilitating
degradation of pericellular type I collagen; however, we did
not observe invasion of MT1-MMP expressing Bowes
melanoma cells into type I collagen gels, even though
MT1-MMP is expressed at sufficient levels to activate pro-
MMP-2. One possible explanation is that the MT1-MMP
activity in the two cell types may not be equivalent due to
differences in surface enzyme expression levels or in levels
of specific TIMP in the two cell types. Alternatively, failure of
the Bowes melanoma cells to invade into type I collagen
may reflect the need for the participation of specific soluble
collagenases in these cells. It has been shown that inhibiting
MMP-1 expression in melanoma cells by anti-sense DNA
greatly inhibits invasion into type I collagen (Durko et al,
1997). Previous studies also showed that activated MMP-1
in certain melanoma cells stimulates invasion of these cells
into gels containing native type I collagen, whereas
expressing the latent form of this collagenase is ineffective
(Benbow et al, 1999). Neither parental, mock, nor MT1-
MMP-transfected melanoma cells used in this study
produce detectable levels of collagenases such as MMP-
1, MMP-8, or MMP-13 (not shown). Bowes melanoma cells
may therefore be a useful model for determining the relative
importance of soluble collagenases and gelatinases in
melanoma invasion into fibrillar collagen-rich tissues such
as dermis. This study is currently focused therefore on using
these cells as a model to address the relative importance of
collagenase expression for promoting the invasion of these
cells into type I collagen gels.
Tumor cell/laminin interactions also play a key part in
tumor metastasis (Mackay et al, 1994; Reich and Martin,
1996; Takahashi et al, 1999; Patarroyo et al, 2002). For
example, specific inhibitors that disrupt tumor cell/laminin
interactions inhibit invasion (Yamamura et al, 1993). In this
study, we demonstrate that antibodies against a6b1 integrin
inhibit melanoma invasion into matrigel, whereas antibodies
against a2b1 or a3b1 integrins have a limited effect. This
suggests that MT1-MMP expressing melanoma cells utilize
laminin within the matrigel as an important ECM component
in their invasion. By analyzing migration to laminin and to
types I and IV collagens, we further demonstrated that MT1-
MMP expressing cells exhibit increased motility on laminin
that is sensitive to anti-a6b1 integrin antibodies. This result
is reminiscent of recent reports demonstrating that MT1-
MMP enhances tumor cell migration to type I collagen and
laminin-5 (Koshikawa et al, 2000; Rozanov et al, 2001);
however, in those studies, the catalytic activity of MT1-
MMP was required for increased migration. In the case of
laminin-5, this is because MT1-MMP cleaves laminin-5 to
expose a cryptic migration-promoting site on the molecule
(Koshikawa et al, 2000). In our experiments, which utilize
laminin-1, the catalytic activity of MT1-MMP is not required
for the observed increase in tumor migration. These results
suggest that increased migration in the MT1-MMP Bowes
melanoma cells may be reflective of altered signal trans-
duction pathways related to the expression of this protease
on the cell surface.
The dysregulated growth of tumors is tightly linked to
progression and metastasis. We observed that MT1-MMP
expression in Bowes melanoma cells leads to increased
growth of these tumors in vitro. Enhanced growth of the
MT1-MMP expressing melanoma cells was observed in
two-dimensional cultures and in three-dimensional cultures
using tumor cells embedded in agarose or matrigel. MT1-
MMP expression has been linked to increased tumor growth
in vivo and to increased angiogenesis of tumors (Deryugina
et al, 2002; Sounni et al, 2002a,b); however, those studies
have indicated that MT1-MMP had no direct effect on
growth of tumor cells in vitro. In contrast, this study
indicates that MT1-MMP can directly enhance the growth
of tumor cells. Importantly, BB94 abrogated the enhanced
growth properties of these tumors in all of the culture
conditions examined, indicating that the catalytic activity of
MMP is important for the observed increases in growth.
MMP could act to facilitate growth by modifying the
expression and/or activation of latent growth and/or survival
factors (McCawley and Matrisian, 2001). Catalytically active
MMP-2 can generate active transforming growth factor-b
from the latent form expressed on cell surfaces (Yu and
Stamenkovic, 2000), which may facilitate anchorage in-
dependent growth. Furthermore, recent studies have shown
that the hydroxymate MMP inhibitor, GM6001, induces
apoptosis in osteoblast cells cultured in three-dimensional
collagen gels, probably by inhibiting production of the
active form of transforming growth factor-b which was
produced by catalytically active MT1-MMP (Karsdal et al,
2002). It is also possible that cell surface expression of
MT1-MMP in melanoma cells may transduce specific
growth/survival promoting signals as has been shown in
other cells (Gingras et al, 2001; Rozanov et al, 2002).
Regardless of the exact mechanism, these results suggest
that MT1-MMP expression in some melanoma cells may
directly stimulate the growth of the tumor cells. This effect
could be important for enhancing growth in the vicinity of
basement membranes and facilitate entry/growth of tumors
into adjacent tissues. MT1-MMP enhanced growth of
melanoma cells may also be important for regulating tumor
dormancy, as has previously been proposed for urakinase-
type plasminogen activator receptor (uPAR) expression in
certain tumor types, which can activate growth factor
receptors in a ligand independent fashion when combined
with specific integrins on tumor cell surfaces (Liu et al,
2002).
We also demonstrated that MT1-MMP stimulates tumor-
igenicity of stable transfectants following intradermal injec-
tion in immunocompromised mice consistent with the
previous observations (Sounni et al, 2002a). Although the
details of the mechanisms of MT1-MMP-mediated tumor
growth are not known, it is possible that MT1-MMP may
function to degrade matrix proteins by itself and/or activate
MMP-2 in the process (Sato et al, 1997). Previous studies
demonstrated that melanoma growth and metastasis in
MMP-2 / mice were significantly inhibited compared
with heterozygous littermates (Itoh et al, 1998), emphasizing
the importance of MMP-2 activity in melanoma growth and
metastasis. It has been reported that expression of MT1-
MMP stimulates epithelial cell invasion into type I collagen
or fibrin gels without involvement of MMP-2 (Hotary et al,
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2000, 2002). Recently, MT1-MMP and laminin-5 have also
been linked to the remodeling of tumor parenchyma leading
to the formation of vascular-like structures that may help
facilitate tumor growth and survival in vivo (Seftor et al,
2001). Thus, whether MT1-MMP contributes to melanoma
growth directly or indirectly through activation of pro-MMP-
2 remains to be evaluated.
In conclusion, this study demonstrate that catalytically
active MT1-MMP and MMP-2 can lead to enhanced
migration, invasion, and growth of melanoma cells by
multiple mechanisms that are both dependent and inde-
pendent of the catalytic activity of the enzymes. The results
further suggest that the interaction of MT1-MMP/MMP2
expressing melanoma cells with basement membranes may
be critically altered by the expression and activation of
these two proteases to facilitate growth and invasion into
adjacent tissues (Albini, 1998). By defining the importance
of both catalytic and noncatalytic functions of MMP in
tumor progression it may be possible to develop more
broad-based approaches for inhibiting MMP activity in
tumor invasion and metastasis.
Materials and Methods
Cell line Human melanoma cell line (Bowes) and human fibro-
sarcoma cell line (HT-1080) were obtained from the American Type
Tissue Culture Collection (ATCC). These cell lines were cultured in
essential minimal Eagle’s medium (EMEM) supplemented with
10% fetal bovine serum (FBS), nonessential amino acids, and
sodium pyruvate. The Institutional Animal Care and Use Committee
(IACUC) provided full approval for this study.
Reagents A general MMP inhibitor (BB94) was supplied from
British Biotech (Oxford, UK). Concanavalin A was purchased from
Sigma (St Louis, Missouri). Fugene6 was purchased from Roche
Applied Science (Indianapolis, Indiana). G418 was purchased from
Life Technologies (Gaithersburg, Maryland). Murine monoclonal
antibody (M2) generated against flag peptide was purchased from
Stratagene (Palo Alto, California). Aprotinin, e-amino-n-caproic
acid, and type IV collagen were purchased from Sigma. Type I
collagen was purchased from Cohesion (Palo Alto, California).
Laminin-1 was purchased from Biomedical Technologies Inc.
(Stoughton, Massachusetts). Anti-a2 (clone P1E6), anti-a3 (ACS-
1), and anti-a6 (clone NKI-GoH3) integrin monoclonal antibodies
were purchased from Chemicon (Temecula, California). Anti-b1
integrin monoclonal antibody (P5D2) was a gift of Dr Elizabeth
Wayner (University of Washington, Seattle, Washington) (Skubitz
et al, 1996).
Plasmids For the construction of MT1-MMP-FLAG, a 50 primer 50-
ACCATGTCTCCCGC CCCAAGACCCTCCCGT-30, and 30 primer,
50-GTCACTTGTCATCGTCGTCCTTGTAGTC GACCTTGTCCAG-
CAGGGAACGCTGGCAGTA-30 coding an extension of the FLAG
tag, were phosphorylated with T4 polynucleotide kinase and used
to amplify human MT1-MMP cDNA using high fidelity polymerase
pfu for 15 cycles. The resulting polymerase chain reaction fragment
was subsequently cloned into the EcoR1 site of pCR3.1 expression
vector as described (Pei and Weiss, 1996). Recombinant plasmids
were screened initially by restriction analysis for insert orientation.
Nested primers were used to sequence both strands and identify
an error-free vector.
Full length of flag-tagged MT1-MMP was subcloned into
pIRES2-EGFP (Clontech, Palo Alto, California) through NheI/EcoRI
site. The sequence of the resulting insert was verified by the
Microchemical Facility at the University of Minnesota (Minneapolis,
Minnesota).
Transfections Bowes melanoma cells (3  104 cells per mL per
well) were cultured overnight in 24-well plates in the culture media.
Cells were washed with EMEM-serum free and then incubated with
100 mL of mixture of DNA (3 mg) and Fugene6 (5 mL) in EMEM
containing 10% FBS for 6 h at 371C. The cells were then incubated
in culture media overnight, after which time they were grown in the
presence of 1 mg per mL G418. The drug-resistant cells were
harvested and sorted based on the expression of enhanced green
fluorescence protein (EGFP) by the Flow Cytometry Core Facility at
the Cancer Center of University of Minnesota. The EGFP-positive
population was then cultured and sorted again. The stability of the
expression of EGFP was monitored by flow cytometric analysis
and the expression of MT1-MMP was monitored by western
blotting as shown in the text.
Gelatin/zymography The conditioned media were separated on
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–
PAGE; 10% of separating gel with 5% of stacking gel) containing
1 mg gelatin per mL as described previously (Pei and Weiss, 1996).
Cells (3  105 cells per well) were cultured in the growth media in
six-well plates overnight. Cells were washed with warmed EMEM-
serum free five times and then incubated in the absence or
presence of 5 mM BB94, 100 mg aprotinin per mL, and 200 mg
e-amino-n-caproic acid per mL overnight. Conditioned media (10
mL) were mixed with SDS sample buffer (6% SDS, 0.16 M Tris, 30%
glycerol, and 0.2% bromophenol blue) and then separated on
SDS–PAGE containing 1 mg gelatin per mL. The gels were washed
two times with 2.5% Triton-X100 and then incubated in buffer
containing 20 mM Tris–HCl (pH 7.5), 1.25% Triton-X100, 5 mM
CaCl2, and 1 mM ZnCl2 overnight at 371C. The gels were stained
with Coomassie blue and destained. As a standard, conditioned
media prepared from concanavalin A-stimulated HT1080 cells was
used to localize pro- (p), intermediate- (i), and active- (a) forms of
MMP-2.
Western blotting Proteins were separated by SDS–PAGE and
then transferred on to nylon membranes. Membranes were
blocked by shaking with phosphate-buffered saline containing
5% dry milk and then incubated with appropriate primary
antibodies at concentrations of 2 mg per mL for 1 h at room
temperature. Membranes were incubated with the corresponding
secondary antibodies conjugated to horseradish peroxidase for 1 h
at room temperature. Reactive proteins were detected by
enhanced chemiluminescence (Amersham Pharmacia Biotech,
Piscataway, New Jersey).
Cell invasion assays Human melanoma cell invasion was
evaluated using matrigel and type I collagen as described
previously (Faassen et al, 1992; Knutson et al, 1996). Matrigel
(final concentration of 4 mg per mL) or type I collagen (final
concentration of 2.2 mg per mL) was mixed with in EMEM 2% FBS
and then gelled in six-well plates (1.5 mL per well) by incubating at
371C for 5 h. Cells were harvested by trypsin/EDTA, washed four
times, and resuspended at a concentration of 104 cells per mL in
EMEM containing 2% FBS. One milliliter of cell suspension was
added to each well and incubated at 371C for 72 h. Cell invasion
was measured using an inverted phase contrast microscope
(Nikon, TE200) equipped with a calibrated fine focus knob, at
100  magnification. The fine focus knob was calibrated using a
collagen gel sandwiched between two coverslip-separated glass
slides to account for the refractive properties of the gel. The
number of invading cells was determined optically by quantifying
the number of cells at successive 20 mm (1 cell diameter) intervals
in six randomly selected fields. Quantitation was made at
increasing depth within the gels until no additional cells were
detected. At least 100 cells were counted from each cell and data
are represented as the percentage of cells penetrating the gels and
results are represented as mean  SD of triplicate gels.
Colony formation in matrigel was evaluated essentially as
described above. Cells were embedded in matrigel (4 mg per mL)
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at a concentration of 104 cells per mL. Cells were then incubated at
371C for 10 d with changing media every other day. Colony formation
was observed using an inverted microscope equipped with a spot
camera (Model 3.2.0, Diagnostic, Sterling Heights, MI). Several
pictures were taken and representative fields are shown in the results.
Migration assays Migration assays were performed as described
previously (Iida et al, 2001). Briefly, cells were harvested as
described above and then adjusted to a concentration of 5  105
cells per mL in EMEM-serum free. An aliquot of 100 mL of the cell
suspension was added into the upper chambers of the transwells
(catalog no. 3422, Costar, Cambridge, Massachusetts). The lower
wells were filled with 600 mL of ligand at 10 mg per mL in EMEM-
serum free. Inhibitors such as BB94 and anti-integrin antibodies
were added into both upper and lower chambers. Cells were
cultured for 4 h at 371C and then stained with Diff-Quick solution.
The number of cells migrated on the beneath of membranes were
counted by choosing random 3 three fields in each membrane.
Experiments were repeated at least three times and results are
expressed as mean  SD from one representative experiment.
Proliferation assays in two-dimensional culture Melanoma
cells were cultured in 12-well plates at density of 2  104/2 mL
per well in EMEM culture media. Cells were cultured for 10 d with
changing media every other day. The numbers of cells were
counted visually with a hemocytometer. Experiments were re-
peated at least three times and results are expressed as
mean  SD from one representative experiment.
Soft agarose colony forming assays The growth/colony forming
potential of melanoma cells was studied in agarose as described
previously (Wesley et al, 1999). Briefly, the top layer, consisting of
5000 viable cells suspended in 0.3% agarose of EMEM supple-
mented with 10% FBS, nonessential amino acids, and sodium
pyruvate, was overlaid on a 1% agarose layer in six well-plates.
Ten days after seeding, colonies over 100 mm in diameter were
counted under a light microscope. The data are presented as the
mean and SD of triplicates plates.
In vivo growth assays For tumor growth assays in vivo, we used
a strain NOD.CB17-Prkdcscid/J mice (3–5 wk old, female, Jackson
Laboratory, Bar Harbor, Maine). These studies were performed in
accordance with Institutional Animal Care Use Committee (IACUC)
of the University of Minnesota. Melanoma cells transfected with
MT1-MMP or vector alone (mock) were injected intradermally (i.d.)
into both right and left flanks with a Hamilton syringe attached with
a 30G1/2 needle at 105 cells/10 mL per site. Tumor growth was
monitored for 4 to 6 wk after the injection by caliper measurements
of length (longest diameter) and width (perpendicular to length).
Tumor volume was estimated by the following calculation (Ding
et al, 2003):
Tumor volume ðmm3Þ ¼ ða  b2  3:14Þ=6
Where in a¼ length, b¼width
Statistical significance was calculated by Student’s two-tailed
t-test. p values less than 0.05 are considered as statistically
significant.
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